Not Currently Updated

I started documenting stock spam in October 2005, but in November 2005, the quantity of stock spam became so large that I put it on hold. In mid-May 2006 I decided to take it up again on a trial basis, limiting reports to one per day per stock, but I gave up again in mid-June 2006 as the workload was still excessive relative to the importance of the issue. Others continued to do a fine job of it -- see the links at left -- but according to statistics from spamnation, the problem peaked in 2007 and dropped off abruptly in 2008, becoming a mere trickle in 2009/10. I'm leaving this blog online as a historical reference, but I have no further plans to update it, and I've disabled comments because nobody has tried to post anything but spam comments here in a long time.

Tuesday, October 04, 2005

Watch this St0ckTprade

ATTENTION INVESTING PUBLIC



ASCE . PK
Recent Trading Range: $.80 - $.90
Expected Trading Range: $1.50 - $2.00
ASCE . PK


BELLEVUE, WA. September 14, 2005 . Ascentia Biomedical Corporation (OTC Pink Sheets; ASCE), a leading researcher and developer of efficacious
pharmaceuticals, compounds and other products, announces it has received an initial commitment for up to $1 million in funding for continued research
particularly in anti-cancer compounds and for organizational growth.


BELLEVUE, WA. September 27th, 2005 . Ascentia Biomedical Corporation (OTC Pink Sheets; ASCE), a leading researcher and developer of efficacious
pharmaceuticals, compounds and other products, announces the addition of Dr. Philip Mease to its Scientific Advisory Board. Dr. James Clagett,
President and CEO of Ascentia said, .We are privileged to have such an internationally recognized rheumatologist who has a distinguished career in the
clinical development of therapies for rheumatic diseases.  Dr. Mease.s experience in clinical drug discovery along with his respected relationship with
drug regulatory agencies will greatly assist Ascentia in its drug discovery and commercialization program..


Dr. Mease is Chief of the Rheumatology Clinical Research Division at Swedish Hospital, Clinical Professor at the University of Washington, and founder
of Seattle Rheumatology Associates.  Dr. Mease graduated from Stanford University Medical School and completed his medical training at University of
Washington, Seattle.


About Ascentia Biomedical Corporation

Our focus is SOLUTIONS through RESEARCH and DISCOVERY. Ascentia is developing and commercializing new pharmaceutical and biomedical products for
application in a number of areas, including treatment for asthma, arthritis, psoriasis and cancer.  Initially, a majority of these products will be
secured through direct purchase or through licensing. As the Company grows and evolves, more products will be developed internally. Ascentia is focused
on therapies for cancer and diseases of inflammation.


Forward-Looking Statements



This release may contain forward-looking statements that involve risks

and uncertainties. These statements do not constitute representations

or promises. Rather, these statements express opinions, hopes and

desires that may not be based on objective or factual criteria or

measurable results. No one should rely on such statements for any

purpose except as specifically stated



To get taken off the list email NOSTK@Yahoo.com

No comments: